Discovery reported by UBC-led team

A team of researchers led by the University of British Columbia (UBC) has reported identifying two chemical compounds that demonstrated potent antiviral activity across a broad range of viruses. The findings were highlighted by UBC Science on February 6, 2026.

According to the report, the compounds showed strong antiviral effects in laboratory testing and were able to protect mice from infection with influenza A, a common cause of seasonal flu outbreaks.

Protection seen in an influenza A mouse model

The source information states that the two compounds protected mice exposed to influenza A infection. Such animal studies are typically used to evaluate whether an experimental antiviral can reduce illness or improve survival in controlled conditions before any consideration of human studies.

The report describes the compounds as having “wide-ranging” antiviral activity, indicating they may act against multiple viruses rather than targeting a single strain. The source does not provide the names of the compounds, their chemical class, or details about the exact viruses tested beyond influenza A.

Broad-spectrum antiviral focus

Broad-spectrum antivirals are designed to work against more than one virus, which can be important when the exact cause of a respiratory infection is not immediately known or when viruses evolve over time. The UBC update frames the discovery in this broad-spectrum context.

The report does not specify dosing, route of administration, or how the compounds work at a molecular level. It also does not state whether the compounds were compared with existing flu antivirals in the mouse experiments.

What the update does and does not claim

The UBC Science item describes the compounds as having “potent” antiviral activity and highlights protection in mice from influenza A infection. However, the source information does not mention human testing, regulatory status, or timelines for clinical development.

No guidance is provided in the source about using these compounds for treatment outside research settings. The report presents the work as a scientific discovery from a UBC-led research team.